Global Curative Therapeutics Market - 2025 -2033
Market Size
The global curative therapeutics market size reached US$ 19.94 Billion in 2024 from US$ 18.34 Billion in 2023 and is expected to reach US$ 44.95 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.
Market Overview
The curative therapeutics market is emerging as one of the most transformative segments in modern medicine, driven by therapies designed to correct or permanently resolve the underlying cause of disease rather than manage symptoms. It encompasses biology-modifying drugs, gene therapies, and genetically engineered cell therapies that offer the potential for one-time interventions with long-lasting or lifelong benefits. Oncology remains the largest application area, especially through CAR-T and other advanced cell therapies, while rare genetic disorders and certain infectious diseases represent fast-growing opportunities. Despite challenges related to affordability, durability of effect, and access, the sector is expected to remain a strategic focus for industry stakeholders, given its potential to redefine standards of care and deliver curative outcomes across multiple disease areas.
Curative Therapeutics Market Dynamics
Drivers:
Growing recognition for rare and orphan diseases is significantly driving the curative therapeutics market growth
The growing recognition of rare and orphan diseases is one of the most significant drivers of the curative therapeutics market, as it creates both an urgent medical need and a supportive policy environment for innovation. Rare diseases, by definition, affect small patient populations, yet collectively they represent millions of individuals worldwide who often lack effective treatment options. For many of these conditions, traditional therapies provide only symptomatic relief, whereas curative approaches such as gene and cell therapies can directly target the genetic or molecular root cause. This alignment of unmet need with scientific feasibility has made orphan diseases a natural entry point for curative technologies.
Regulatory agencies have amplified this momentum by offering orphan drug designations and fast-track approvals to developers working in this space. For instance, Novartis’s Zolgensma, approved for spinal muscular atrophy, and bluebird bio’s Zynteglo for beta-thalassemia, demonstrate how gene therapies can achieve transformative clinical outcomes in previously untreatable populations. Beyond these high-profile cases, curative pipelines are expanding into hemophilia, sickle cell disease, and inherited retinal disorders, with each success story reinforcing investor and payer confidence.
Restraints:
High upfront therapy costs and affordability concerns are hampering the growth of the curative therapeutics market
High upfront therapy costs and affordability concerns remain one of the most pressing restraints on the curative therapeutics market, as they create significant barriers for patients, healthcare systems, and payers. Unlike traditional treatments that spread costs over time, many curative therapies are priced in the range of hundreds of thousands to millions of dollars for a single administration, creating what is often termed a “sticker shock” effect.
For instance, Novartis’s gene therapy Zolgensma for spinal muscular atrophy is priced at over $2.1 million, making it one of the most expensive treatments globally, while bluebird bio’s Zynteglo for beta-thalassemia carries a price tag of $2.8 million in the U.S. Although these therapies can offer lifelong benefits and offset the costs of chronic care, payers face challenges in absorbing such high upfront expenditures within annual budgets. This issue is particularly pronounced in countries with fragmented healthcare systems or limited insurance coverage, where access is restricted to only a fraction of eligible patients.
Affordability concerns exacerbate health inequities, as patients in low- and middle-income countries are largely excluded from access to these life-changing interventions. The result is a paradox, while curative therapeutics promise to revolutionize healthcare by addressing the root causes of diseases, their high price points slow adoption, limit reimbursement, and raise ethical concerns about who can truly benefit. Until scalable manufacturing, innovative financing models, and broader payer acceptance are established, high upfront costs will continue to be a major hurdle restraining market growth.
Segmentation Analysis
The global curative therapeutics market is segmented based on therapy type, indication, end-user, and region.
The oncology segment from the indication is dominating the curative therapeutics market with a 22.31% share in 2024
Oncology represents the dominant segment in the curative therapeutics market, largely due to the high global burden of cancer, the urgent need for transformative therapies, and the remarkable clinical successes achieved with advanced modalities such as CAR-T cell therapies and gene editing. Cancer remains one of the leading causes of mortality worldwide, with an expected 35.3 million incidence cases by 2050 according to the WHO, driving into innovative solutions that can move beyond palliative or maintenance care toward long-term remission or cure. The approval of CAR-T therapies like Novartis’s Kymriah and Gilead’s Yescarta for hematologic malignancies has demonstrated the potential of curative approaches, achieving durable remissions in patients who previously had limited or no treatment options.
Major and emerging market players are offering cost-effective solutions, further driving the growth of the market. For instance, in January 2025, Immuneel Therapeutics launched India's second CAR-T cell therapy, Qartemi, to treat patients with B-cell Non-Hodgkin Lymphoma (B-NHL), an aggressive form of blood cancer, at less than one-tenth of the price of similar therapies available in Western countries. The results showed that the efficacy and safety of Qartemi are similar to CAR T-cell therapies approved by the US FDA.
Geographical Share Analysis
North America is expected to dominate the global curative therapeutics market with a 42.31% in 2024
North America stands as the dominant region in the global curative therapeutics market, driven by its strong research ecosystem, favorable regulatory framework, and high levels of investment in advanced therapies. The United States, in particular, has pioneered the approval and commercialization of many landmark curative products. For instance, the FDA approved Novartis’s Zolgensma for spinal muscular atrophy and bluebird bio’s Zynteglo for beta-thalassemia, both of which are considered breakthroughs in gene therapy.
Similarly, in April 2024, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved BEQVEZ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.
The region leads in cell-based curative treatments, with CAR-T therapies like Kymriah and Yescarta rapidly gaining traction across oncology centers of excellence. Canada is also progressing in this space, with Health Canada streamlining frameworks for advanced therapy medicinal products. Collectively, the combination of scientific leadership, regulatory support, and clinical adoption cements North America’s position as the dominant market for curative therapeutics, setting benchmarks that other regions are striving to emulate.
Competitive Landscape
Top companies in the curative therapeutics market include Gilead Sciences, Inc., Spark Therapeutics, Inc., Pfizer Inc., Amgen, Inc., Novartis Pharmaceuticals Corporation, bluebird bio, Inc. and Sarepta Therapeutics, Inc., among others.
Key Developments
The global curative therapeutics market size reached US$ 19.94 Billion in 2024 from US$ 18.34 Billion in 2023 and is expected to reach US$ 44.95 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.
Market Overview
The curative therapeutics market is emerging as one of the most transformative segments in modern medicine, driven by therapies designed to correct or permanently resolve the underlying cause of disease rather than manage symptoms. It encompasses biology-modifying drugs, gene therapies, and genetically engineered cell therapies that offer the potential for one-time interventions with long-lasting or lifelong benefits. Oncology remains the largest application area, especially through CAR-T and other advanced cell therapies, while rare genetic disorders and certain infectious diseases represent fast-growing opportunities. Despite challenges related to affordability, durability of effect, and access, the sector is expected to remain a strategic focus for industry stakeholders, given its potential to redefine standards of care and deliver curative outcomes across multiple disease areas.
Curative Therapeutics Market Dynamics
Drivers:
Growing recognition for rare and orphan diseases is significantly driving the curative therapeutics market growth
The growing recognition of rare and orphan diseases is one of the most significant drivers of the curative therapeutics market, as it creates both an urgent medical need and a supportive policy environment for innovation. Rare diseases, by definition, affect small patient populations, yet collectively they represent millions of individuals worldwide who often lack effective treatment options. For many of these conditions, traditional therapies provide only symptomatic relief, whereas curative approaches such as gene and cell therapies can directly target the genetic or molecular root cause. This alignment of unmet need with scientific feasibility has made orphan diseases a natural entry point for curative technologies.
Regulatory agencies have amplified this momentum by offering orphan drug designations and fast-track approvals to developers working in this space. For instance, Novartis’s Zolgensma, approved for spinal muscular atrophy, and bluebird bio’s Zynteglo for beta-thalassemia, demonstrate how gene therapies can achieve transformative clinical outcomes in previously untreatable populations. Beyond these high-profile cases, curative pipelines are expanding into hemophilia, sickle cell disease, and inherited retinal disorders, with each success story reinforcing investor and payer confidence.
Restraints:
High upfront therapy costs and affordability concerns are hampering the growth of the curative therapeutics market
High upfront therapy costs and affordability concerns remain one of the most pressing restraints on the curative therapeutics market, as they create significant barriers for patients, healthcare systems, and payers. Unlike traditional treatments that spread costs over time, many curative therapies are priced in the range of hundreds of thousands to millions of dollars for a single administration, creating what is often termed a “sticker shock” effect.
For instance, Novartis’s gene therapy Zolgensma for spinal muscular atrophy is priced at over $2.1 million, making it one of the most expensive treatments globally, while bluebird bio’s Zynteglo for beta-thalassemia carries a price tag of $2.8 million in the U.S. Although these therapies can offer lifelong benefits and offset the costs of chronic care, payers face challenges in absorbing such high upfront expenditures within annual budgets. This issue is particularly pronounced in countries with fragmented healthcare systems or limited insurance coverage, where access is restricted to only a fraction of eligible patients.
Affordability concerns exacerbate health inequities, as patients in low- and middle-income countries are largely excluded from access to these life-changing interventions. The result is a paradox, while curative therapeutics promise to revolutionize healthcare by addressing the root causes of diseases, their high price points slow adoption, limit reimbursement, and raise ethical concerns about who can truly benefit. Until scalable manufacturing, innovative financing models, and broader payer acceptance are established, high upfront costs will continue to be a major hurdle restraining market growth.
Segmentation Analysis
The global curative therapeutics market is segmented based on therapy type, indication, end-user, and region.
The oncology segment from the indication is dominating the curative therapeutics market with a 22.31% share in 2024
Oncology represents the dominant segment in the curative therapeutics market, largely due to the high global burden of cancer, the urgent need for transformative therapies, and the remarkable clinical successes achieved with advanced modalities such as CAR-T cell therapies and gene editing. Cancer remains one of the leading causes of mortality worldwide, with an expected 35.3 million incidence cases by 2050 according to the WHO, driving into innovative solutions that can move beyond palliative or maintenance care toward long-term remission or cure. The approval of CAR-T therapies like Novartis’s Kymriah and Gilead’s Yescarta for hematologic malignancies has demonstrated the potential of curative approaches, achieving durable remissions in patients who previously had limited or no treatment options.
Major and emerging market players are offering cost-effective solutions, further driving the growth of the market. For instance, in January 2025, Immuneel Therapeutics launched India's second CAR-T cell therapy, Qartemi, to treat patients with B-cell Non-Hodgkin Lymphoma (B-NHL), an aggressive form of blood cancer, at less than one-tenth of the price of similar therapies available in Western countries. The results showed that the efficacy and safety of Qartemi are similar to CAR T-cell therapies approved by the US FDA.
Geographical Share Analysis
North America is expected to dominate the global curative therapeutics market with a 42.31% in 2024
North America stands as the dominant region in the global curative therapeutics market, driven by its strong research ecosystem, favorable regulatory framework, and high levels of investment in advanced therapies. The United States, in particular, has pioneered the approval and commercialization of many landmark curative products. For instance, the FDA approved Novartis’s Zolgensma for spinal muscular atrophy and bluebird bio’s Zynteglo for beta-thalassemia, both of which are considered breakthroughs in gene therapy.
Similarly, in April 2024, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved BEQVEZ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.
The region leads in cell-based curative treatments, with CAR-T therapies like Kymriah and Yescarta rapidly gaining traction across oncology centers of excellence. Canada is also progressing in this space, with Health Canada streamlining frameworks for advanced therapy medicinal products. Collectively, the combination of scientific leadership, regulatory support, and clinical adoption cements North America’s position as the dominant market for curative therapeutics, setting benchmarks that other regions are striving to emulate.
Competitive Landscape
Top companies in the curative therapeutics market include Gilead Sciences, Inc., Spark Therapeutics, Inc., Pfizer Inc., Amgen, Inc., Novartis Pharmaceuticals Corporation, bluebird bio, Inc. and Sarepta Therapeutics, Inc., among others.
Key Developments
- In May 2025, Sarepta Therapeutics, Inc. announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals aged 3 to less than 8 years old, who do not have any deletions in exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. This is the first global approval to include individuals younger than 4 years of age.
- In February 2025, CSL Behring announced the four-year results from the pivotal HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX (etranacogene dezaparvovec-drlb) gene therapy for adults living with hemophilia B.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy Type
2.4. Snippet by Indication
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Growing Recognition for Rare and Orphan Diseases
3.1.1.2. Evolving Reimbursement Models for High-Value Therapies
3.1.2. Restraints
3.1.2.1. High Upfront Therapy Costs and Affordability Concerns
3.1.2.2. Complex Manufacturing and Supply Chain Bottlenecks
3.1.3. Opportunity
3.1.3.1. In-vivo Gene Editing and Non-viral Delivery
3.1.3.2. Curative Combos and Sequencing
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. CURATIVE THERAPEUTICS MARKET, BY THERAPY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
5.1.2. Market Attractiveness Index, By Therapy Type
5.2. Biology-Modifying Drugs*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Gene Therapies
5.4. Cell Therapies
5.5. Others
6. CURATIVE THERAPEUTICS MARKET, BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Rare Genetic Disorders
6.4. Infectious Diseases
6.5. Hematology
6.6. Ophthalmology
6.7. Neurology
6.8. Cardiometabolic Disorders
6.9. Others
7. CURATIVE THERAPEUTICS MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Academic and Research Institutes
7.5. Others
8. CURATIVE THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Gilead Sciences, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Spark Therapeutics, Inc.
10.3. Pfizer Inc.
10.4. Amgen, Inc.
10.5. Novartis Pharmaceuticals Corporation
10.6. bluebird bio, Inc.
10.7. Sarepta Therapeutics, Inc. (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy Type
2.4. Snippet by Indication
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Growing Recognition for Rare and Orphan Diseases
3.1.1.2. Evolving Reimbursement Models for High-Value Therapies
3.1.2. Restraints
3.1.2.1. High Upfront Therapy Costs and Affordability Concerns
3.1.2.2. Complex Manufacturing and Supply Chain Bottlenecks
3.1.3. Opportunity
3.1.3.1. In-vivo Gene Editing and Non-viral Delivery
3.1.3.2. Curative Combos and Sequencing
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. CURATIVE THERAPEUTICS MARKET, BY THERAPY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
5.1.2. Market Attractiveness Index, By Therapy Type
5.2. Biology-Modifying Drugs*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Gene Therapies
5.4. Cell Therapies
5.5. Others
6. CURATIVE THERAPEUTICS MARKET, BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Rare Genetic Disorders
6.4. Infectious Diseases
6.5. Hematology
6.6. Ophthalmology
6.7. Neurology
6.8. Cardiometabolic Disorders
6.9. Others
7. CURATIVE THERAPEUTICS MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Academic and Research Institutes
7.5. Others
8. CURATIVE THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Gilead Sciences, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Spark Therapeutics, Inc.
10.3. Pfizer Inc.
10.4. Amgen, Inc.
10.5. Novartis Pharmaceuticals Corporation
10.6. bluebird bio, Inc.
10.7. Sarepta Therapeutics, Inc. (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Curative Therapeutics Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Curative Therapeutics Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Curative Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Curative Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Curative Therapeutics Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 7 Global Curative Therapeutics Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global Curative Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global Curative Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Curative Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 14 North America Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 18 Europe Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 26 South America Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Gilead Sciences, Inc.: Overview
Table 34 Gilead Sciences, Inc.: Product Portfolio
Table 35 Gilead Sciences, Inc.: Key Developments
Table 36 Spark Therapeutics, Inc.: Overview
Table 37 Spark Therapeutics, Inc.: Product Portfolio
Table 38 Spark Therapeutics, Inc.: Key Developments
Table 39 Pfizer Inc.: Overview
Table 40 Pfizer Inc.: Product Portfolio
Table 41 Pfizer Inc.: Key Developments
Table 42 Amgen, Inc.: Overview
Table 43 Amgen, Inc.: Product Portfolio
Table 44 Amgen, Inc.: Key Developments
Table 45 Novartis Pharmaceuticals Corporation: Overview
Table 46 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 47 Novartis Pharmaceuticals Corporation: Key Developments
Table 48 bluebird bio, Inc.: Overview
Table 49 bluebird bio, Inc.: Product Portfolio
Table 50 bluebird bio, Inc.: Key Developments
Table 51 Sarepta Therapeutics, Inc.: Overview
Table 52 Sarepta Therapeutics, Inc.: Product Portfolio
Table 53 Sarepta Therapeutics, Inc.: Key Developments
Table 1 Global Curative Therapeutics Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Curative Therapeutics Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Curative Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Curative Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Curative Therapeutics Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 7 Global Curative Therapeutics Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global Curative Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global Curative Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Curative Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 14 North America Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 18 Europe Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 26 South America Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Curative Therapeutics Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Curative Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Curative Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Gilead Sciences, Inc.: Overview
Table 34 Gilead Sciences, Inc.: Product Portfolio
Table 35 Gilead Sciences, Inc.: Key Developments
Table 36 Spark Therapeutics, Inc.: Overview
Table 37 Spark Therapeutics, Inc.: Product Portfolio
Table 38 Spark Therapeutics, Inc.: Key Developments
Table 39 Pfizer Inc.: Overview
Table 40 Pfizer Inc.: Product Portfolio
Table 41 Pfizer Inc.: Key Developments
Table 42 Amgen, Inc.: Overview
Table 43 Amgen, Inc.: Product Portfolio
Table 44 Amgen, Inc.: Key Developments
Table 45 Novartis Pharmaceuticals Corporation: Overview
Table 46 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 47 Novartis Pharmaceuticals Corporation: Key Developments
Table 48 bluebird bio, Inc.: Overview
Table 49 bluebird bio, Inc.: Product Portfolio
Table 50 bluebird bio, Inc.: Key Developments
Table 51 Sarepta Therapeutics, Inc.: Overview
Table 52 Sarepta Therapeutics, Inc.: Product Portfolio
Table 53 Sarepta Therapeutics, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 3 Global Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global Curative Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Curative Therapeutics Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 7 Biology-Modifying Drugs Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 8 Gene Therapies Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Cell Therapies Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Others Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Curative Therapeutics Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 12 Oncology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Rare Genetic Disorders Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Infectious Diseases Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Hematology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 16 Ophthalmology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Neurology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Cardiometabolic Disorders Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Curative Therapeutics Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 21 Hospitals End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Specialty Clinics End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 23 Academic and Research Institutes End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 Others End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Curative Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 28 North America Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 29 North America Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 30 North America Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 33 Europe Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 34 Europe Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 35 Europe Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 39 Asia-Pacific Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 40 Asia-Pacific Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 43 South America Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 44 South America Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 45 South America Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 48 Middle East and Africa Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 49 Middle East and Africa Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 50 Gilead Sciences, Inc.: Financials
Figure 51 Spark Therapeutics, Inc.: Financials
Figure 52 Pfizer Inc.: Financials
Figure 53 Amgen, Inc.: Financials
Figure 54 Novartis Pharmaceuticals Corporation: Financials
Figure 55 bluebird bio, Inc.: Financials
Figure 56 Sarepta Therapeutics, Inc.: Financials
Figure 1 Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 3 Global Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global Curative Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Curative Therapeutics Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 7 Biology-Modifying Drugs Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 8 Gene Therapies Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Cell Therapies Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Others Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Curative Therapeutics Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 12 Oncology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Rare Genetic Disorders Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Infectious Diseases Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Hematology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 16 Ophthalmology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Neurology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Cardiometabolic Disorders Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Indication in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Curative Therapeutics Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 21 Hospitals End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Specialty Clinics End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 23 Academic and Research Institutes End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 Others End-User in Global Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Curative Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 28 North America Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 29 North America Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 30 North America Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 33 Europe Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 34 Europe Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 35 Europe Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 39 Asia-Pacific Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 40 Asia-Pacific Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 43 South America Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 44 South America Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 45 South America Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Curative Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 48 Middle East and Africa Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)
Figure 49 Middle East and Africa Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 50 Gilead Sciences, Inc.: Financials
Figure 51 Spark Therapeutics, Inc.: Financials
Figure 52 Pfizer Inc.: Financials
Figure 53 Amgen, Inc.: Financials
Figure 54 Novartis Pharmaceuticals Corporation: Financials
Figure 55 bluebird bio, Inc.: Financials
Figure 56 Sarepta Therapeutics, Inc.: Financials
